{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:08:49Z","timestamp":1793225329614,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recurrent pulmonary exacerbation due to infection and inflammation remain the major cause of mortality and morbidity in patients with cystic fibrosis (CF). Increased levels of BPI-ANCA have been linked to <jats:italic>Pseudomonas<\/jats:italic> colonization and pulmonary exacerbations in patients with CF. The majority of these studies were done in Europe, and it is unclear whether similar findings are true in CF patients who lives in United States. In our single center study of 47 patients with CF, the prevalence of BPI-ANCA was 19% at baseline and 15% at annual follow-up visit. Overall, there were no statistical differences noted in FEV1 and frequency of pulmonary exacerbations in CF patients who were positive for BPI-ANCA compared to those who were negative for BPI-ANCA. The role of BPI-ANCA in patients with CF still remains unclear.<\/jats:p>","DOI":"10.1038\/s41598-023-45273-2","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T10:05:40Z","timestamp":1698141940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical significance of BPI-ANCA in patients with cystic fibrosis: a single center prospective study"],"prefix":"10.1038","volume":"13","author":[{"given":"Kenneth","family":"Iwuji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaobi","family":"Kanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Stroever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hamood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephany","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"45273_CR1","unstructured":"\u201cAbout Cystic Fibrosis.\u201d CF Foundation, http:\/\/www.cff.org\/What-is-CF\/About-Cystic-Fibrosis\/."},{"key":"45273_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/947934","volume":"2015","author":"U Lindberg","year":"2015","unstructured":"Lindberg, U., Carlsson, M., Hellmark, T. & Segelmark, M. BPI-ANCA provides additional clinical information to anti-Pseudomonas serology: Results from a cohort of 117 Swedish cystic fibrosis patients. J. Immunol. Res. 2015, 947934 (2015).","journal-title":"J. Immunol. Res."},{"issue":"4","key":"45273_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s002960050116","volume":"19","author":"T Cooper","year":"2000","unstructured":"Cooper, T. et al. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal\/permeability-increasing protein and azurocidin. Rheumatol. Int. 19(4), 129\u2013136 (2000).","journal-title":"Rheumatol. Int."},{"issue":"6","key":"45273_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22908","volume":"33","author":"Y Tian","year":"2019","unstructured":"Tian, Y. et al. Clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization. J. Clin. Lab. Anal. 33(6), e22908 (2019).","journal-title":"J. Clin. Lab. Anal."},{"issue":"11","key":"45273_CR5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3389\/fphar.2020.01098","volume":"17","author":"K McQuillan","year":"2020","unstructured":"McQuillan, K. et al. Targeting IgG autoantibodies for improved cytotoxicity of bactericidal permeability increasing protein in cystic fibrosis. Front. Pharmacol. 17(11), 1098 (2020).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"45273_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/ped.2018.0970","volume":"32","author":"K Iwuji","year":"2019","unstructured":"Iwuji, K. et al. Prevalence of bactericidal\/permeability-increasing protein autoantibodies in cystic fibrosis patients: Systematic review and meta-analysis. Pediatr. Allergy Immunol. Pulmonol. 32(2), 45\u201351 (2019).","journal-title":"Pediatr. Allergy Immunol. Pulmonol."},{"key":"45273_CR7","doi-asserted-by":"publisher","first-page":"105994","DOI":"10.1016\/j.rmed.2020.105994","volume":"170","author":"G Hovold","year":"2020","unstructured":"Hovold, G., Lindberg, U., Ljungberg, J. K., Shannon, O. & P\u00e5hlman, L. I. BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization. Respir. Med. 170, 105994 (2020).","journal-title":"Respir. Med."},{"key":"45273_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/370107","volume":"2012","author":"U Lindberg","year":"2012","unstructured":"Lindberg, U., Carlsson, M., L\u00f6fdahl, C. G. & Segelmark, M. BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study. Clin. Dev. Immunol. 2012, 370107 (2012).","journal-title":"Clin. Dev. Immunol."},{"issue":"3","key":"45273_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jcf.2006.10.005","volume":"6","author":"M Carlsson","year":"2007","unstructured":"Carlsson, M. et al. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. J. Cyst. Fibros. 6(3), 228\u2013233 (2007).","journal-title":"J. Cyst. Fibros."},{"issue":"8","key":"45273_CR10","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham, B. L. et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am. J. Respir. Crit. Care Med. 200(8), e70\u2013e88 (2019).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"45273_CR11","volume-title":"Stata Statistical Software: Release 17","author":"StataCorp","year":"2021","unstructured":"StataCorp. Stata Statistical Software: Release 17 (StataCorp LLC, 2021)."},{"issue":"12","key":"45273_CR12","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1002\/ppul.25627","volume":"56","author":"DM Goetz","year":"2021","unstructured":"Goetz, D. M. & Savant, A. P. Review of CFTR modulators 2020. Pediatr. Pulmonol. 56(12), 3595\u20133606. https:\/\/doi.org\/10.1002\/ppul.25627 (2021) (Epub 2021 Aug 18).","journal-title":"Pediatr. Pulmonol."},{"issue":"1","key":"45273_CR13","doi-asserted-by":"publisher","first-page":"7234","DOI":"10.1038\/s41598-019-43652-2","volume":"9","author":"AR Habib","year":"2019","unstructured":"Habib, A. R. et al. A systematic review of the clinical efficacy and safety of CFTR modulators in cystic fibrosis. Sci. Rep. 9(1), 7234 (2019).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45273-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45273-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T17:20:13Z","timestamp":1700587213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45273-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45273"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45273-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"9 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18138"}}